Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
Fuente:
Wiley Open Access
Enregistré dans:
| Auteurs principaux: | Cameron J. McKinzie, Stephanie R. Duehlmeyer, Charissa W. Kam, Julie Safirstein |
|---|---|
| Format: | Artículo Open Access |
| Publié: |
Wiley
2024
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
par: Richard De Vuyst, et autres
Publié: (2024)
par: Richard De Vuyst, et autres
Publié: (2024)
Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
par: Kamyron Jordan, et autres
Publié: (2024)
par: Kamyron Jordan, et autres
Publié: (2024)
Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
par: Hiep Pham, et autres
Publié: (2024)
par: Hiep Pham, et autres
Publié: (2024)
A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor
par: Nora Burdis, et autres
Publié: (2024)
par: Nora Burdis, et autres
Publié: (2024)
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
par: Valeria Daccò, et autres
Publié: (2024)
par: Valeria Daccò, et autres
Publié: (2024)
Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis
par: Emma M. Tillman, et autres
Publié: (2025)
par: Emma M. Tillman, et autres
Publié: (2025)
Diagnosis and treatment of ADHD in pediatric patients during the first year of elexacaftor/tezacaftor/ivacaftor
par: Kimberly Pasley, et autres
Publié: (2024)
par: Kimberly Pasley, et autres
Publié: (2024)
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants
par: Emily Mitchell, et autres
Publié: (2024)
par: Emily Mitchell, et autres
Publié: (2024)
Successful treatment of Stenotrophomonas maltophilia with ceftazidime‐avibactam and aztreonam in an individual with cystic fibrosis: A case report
par: Stephanie Duehlmeyer, et autres
Publié: (2024)
par: Stephanie Duehlmeyer, et autres
Publié: (2024)
Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series
par: Charissa W. Kam, et autres
Publié: (2024)
par: Charissa W. Kam, et autres
Publié: (2024)
Clinical evidence of pancreatic recovery in children with cystic fibrosis on ivacaftor
par: Sydney Walker, et autres
Publié: (2024)
par: Sydney Walker, et autres
Publié: (2024)
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
par: Cindy L. Williams, et autres
Publié: (2025)
par: Cindy L. Williams, et autres
Publié: (2025)
Adapting to change: A description of prescribing practices of asthma controller medications at a pediatric institution
par: Jade Tam‐Williams, et autres
Publié: (2024)
par: Jade Tam‐Williams, et autres
Publié: (2024)
Nutrition and behavioral health in cystic fibrosis: Eating and body image
par: Emma R. Lyons, et autres
Publié: (2024)
par: Emma R. Lyons, et autres
Publié: (2024)
The foregut in cystic fibrosis
par: Christopher Vélez, et autres
Publié: (2024)
par: Christopher Vélez, et autres
Publié: (2024)
Overnutrition in persons with cystic fibrosis on modulator therapy and the relationship to obstructive sleep apnea
par: Aesha M. Jobanputra, et autres
Publié: (2024)
par: Aesha M. Jobanputra, et autres
Publié: (2024)
Time to be blunt: Substance use in cystic fibrosis
par: Sanaz Vaziri, et autres
Publié: (2024)
par: Sanaz Vaziri, et autres
Publié: (2024)
Predicting weight gain in patients with cystic fibrosis on triple combination modulator
par: Kelly L. Stewart, et autres
Publié: (2024)
par: Kelly L. Stewart, et autres
Publié: (2024)
The future of cystic fibrosis: A global perspective
par: Felix Ratjen
Publié: (2024)
par: Felix Ratjen
Publié: (2024)
Prevalence of cannabidiol use in persons with cystic fibrosis
par: Emma M. Tillman, et autres
Publié: (2024)
par: Emma M. Tillman, et autres
Publié: (2024)
Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis
par: Anna M. Georgiopoulos, et autres
Publié: (2024)
par: Anna M. Georgiopoulos, et autres
Publié: (2024)
Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy
par: Brenda M. Morrow, et autres
Publié: (2024)
par: Brenda M. Morrow, et autres
Publié: (2024)
Improving implementation and team communication by integrating a cystic fibrosis transition readiness (CF R.I.S.E.) program into electronic health records
par: Catherine Enochs, et autres
Publié: (2024)
par: Catherine Enochs, et autres
Publié: (2024)
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study
par: Wen Ye, et autres
Publié: (2025)
par: Wen Ye, et autres
Publié: (2025)
Lung T1 MRI assessments in children with mild cystic fibrosis lung disease
par: Clement L. Ren, et autres
Publié: (2024)
par: Clement L. Ren, et autres
Publié: (2024)
Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
par: Nagehan Emiralioğlu, et autres
Publié: (2024)
par: Nagehan Emiralioğlu, et autres
Publié: (2024)
Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study
par: Megan Poulsen, et autres
Publié: (2024)
par: Megan Poulsen, et autres
Publié: (2024)
Codevelopment of a model of care for adults living with cystic fibrosis‐related diabetes
par: Shanal Kumar, et autres
Publié: (2024)
par: Shanal Kumar, et autres
Publié: (2024)
The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis
par: Nicole Green, et autres
Publié: (2024)
par: Nicole Green, et autres
Publié: (2024)
Me, myself, and I: A systematic review of cystic fibrosis and self‐concept
par: Maggie Harrigan, et autres
Publié: (2024)
par: Maggie Harrigan, et autres
Publié: (2024)
BMI increase during early childhood in boys with cystic fibrosis and early adrenarche
par: Gizem Tamer, et autres
Publié: (2024)
par: Gizem Tamer, et autres
Publié: (2024)
Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis
par: CM. López Cárdenes, et autres
Publié: (2024)
par: CM. López Cárdenes, et autres
Publié: (2024)
The rebound effect: Reoccurrence of nasal polyps following discontinuation of a CFTR modulator in a patient with cystic fibrosis sinus disease
par: Brittany A. Wright, et autres
Publié: (2024)
par: Brittany A. Wright, et autres
Publié: (2024)
Comparison of particles in exhaled air and multiple breath washout for assessment of small airway function in children with cystic fibrosis
par: Annelies M. Zwitserloot, et autres
Publié: (2024)
par: Annelies M. Zwitserloot, et autres
Publié: (2024)
Evaluation of otorhinolaryngologic, audiologic, and genetic findings in children with cystic fibrosis: A tertiary care experience
par: Halime Nayır Büyükşahin, et autres
Publié: (2024)
par: Halime Nayır Büyükşahin, et autres
Publié: (2024)
Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
par: Shanal Kumar, et autres
Publié: (2024)
par: Shanal Kumar, et autres
Publié: (2024)
Nebulized granulocyte macrophage‐colony stimulating factor to stabilize lung function in nontuberculous mycobacteria pulmonary disease in cystic fibrosis
par: Colette Biro, et autres
Publié: (2024)
par: Colette Biro, et autres
Publié: (2024)
Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome
par: Brian J. Carroll, et autres
Publié: (2024)
par: Brian J. Carroll, et autres
Publié: (2024)
A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis
par: Sabrina J. Sherwood, et autres
Publié: (2024)
par: Sabrina J. Sherwood, et autres
Publié: (2024)
Implementation and outcomes of a quality improvement project to systematically assess the gross motor skills in school‐aged children with cystic fibrosis
par: Abby Good, et autres
Publié: (2024)
par: Abby Good, et autres
Publié: (2024)
Documents similaires
-
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
par: Richard De Vuyst, et autres
Publié: (2024) -
Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
par: Kamyron Jordan, et autres
Publié: (2024) -
Mental health, sleep, and respiratory health after initiating elexacaftor/tezacaftor/ivacaftor treatment in children with cystic fibrosis
par: Hiep Pham, et autres
Publié: (2024) -
A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor
par: Nora Burdis, et autres
Publié: (2024) -
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6‐11 years with cystic fibrosis in a real‐world setting
par: Valeria Daccò, et autres
Publié: (2024)